UNSPSC 51433505: Cryptenamine

This classification denotes an antihypertensive mixture of closely related hypotensive alkaloids from veratrum album. European Medicines Agency schedules Cryptenamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13498MIG.

UNSPSC 51433505 Cryptenamine, a Commodity code, represents pharmaceutical supply procurement by state and local governments, though recent solicitations show the code captures a much broader range of medications and related pharmaceutical products than the single active pharmaceutical ingredient the code name suggests. State and local buying under this code spans emergency life-support medications (epinephrine, adenosine, labetalol, diltiazem), generic multi-source pharmaceuticals distributed through institutional supply chains, and direct-to-manufacturer prescription fulfillment programs serving state employee health plans and Medicaid populations. Issuing bodies include city fire departments and emergency services (Tampa Fire Rescue), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multi-state networks of state agencies, counties, and municipalities (Minnesota Multistate Cooperative Purchasing Alliance). The code reflects a mix of small, specified-quantity emergency-medication procurements and large-scale, multi-vendor pharmaceutical framework agreements.

Recent activity clusters in Florida and Minnesota, with emerging Texas HHS activity signaling state-level pharmacy benefit modernization. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications on April 24, 2026, with a due date of April 8, 2026 (noted as a due-date anomaly in the source), seeking 370 units of Labetalol, 1,810 units of Epinephrine 1:10,000, 330 units of Adenosine 6mg, and 1,020 units of Diltiazem for Tampa Fire Rescue; the estimated contract value is $40,000.00, with a one-year term and optional two-year renewals plus unilateral 30-day extensions at the City's discretion. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, reflecting early-stage state-level procurement strategy development without identified budget or timeline commitments. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 with a March 26, 2026 response deadline, seeking generic multi-source pharmaceutical and OTC product manufacturers for a two-year contract effective July 1, 2026, distributed through three authorized wholesalers serving state and local government facilities across Minnesota and Oregon. MMCAP's evaluation weighting heavily favors price competitiveness (75 percent), with compliance, EDI capability, and administrative-fee terms comprising the remainder. Tampa's IFB includes a 5 percent bid discount for Small Local Business Enterprise participation, not to exceed $10,000, while MMCAP and Texas HHS materials do not disclose set-aside designations.